These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12147931)

  • 21. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
    Glorioso N; Troffa C; Filigheddu F; Dettori F; Soro A; Parpaglia PP; Collatina S; Pahor M
    Hypertension; 1999 Dec; 34(6):1281-6. PubMed ID: 10601131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are statins effective for simultaneously treating dyslipidemias and hypertension?
    Koh KK; Quon MJ; Waclawiw MA
    Atherosclerosis; 2008 Jan; 196(1):1-8. PubMed ID: 17662294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.
    Ference BA; Cannon CP; Landmesser U; Lüscher TF; Catapano AL; Ray KK
    Eur Heart J; 2018 Jul; 39(27):2540-2545. PubMed ID: 29020411
    [No Abstract]   [Full Text] [Related]  

  • 24. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.
    Yan X; Li Y; Dong Y; Wu Y; Li J; Bian R; Hu D
    Lipids Health Dis; 2019 Jan; 18(1):32. PubMed ID: 30696435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Beneficial effects of statins and angiotensin converting enzyme inhibitors on aggregability of red blood cells in hypertensive patients].
    Korbut RA; Guzik B; Adamek-Guzik T; Korbut R
    Folia Med Cracov; 2006; 47(1-4):37-49. PubMed ID: 18038611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice.
    Prandin MG; Cicero AF; Dormi A; Veronesi M; Cosentino ER; Borghi C
    Nutr Metab Cardiovasc Dis; 2010 Sep; 20(7):512-8. PubMed ID: 19699070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypertension and hypercholesterolemia in the Czech population].
    Wohlfahrt P; Krajčoviechová A; Bruthans J; Cífková R
    Vnitr Lek; 2016; 62(11):863-867. PubMed ID: 28128571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Walczewska J; Siga O; Dzieza-Grudnik A; Krolczyk J; Wizner B; Wolkow PP; Borys A; Kolton-Wroz M; Gryglewska B; Grodzicki T
    J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31443094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
    Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?
    Thavarajah S; Mansoor GA
    Curr Hypertens Rep; 2002 Aug; 4(4):290-7. PubMed ID: 12117456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins and hypertension.
    Pelat M; Balligand JL
    Semin Vasc Med; 2004 Nov; 4(4):367-75. PubMed ID: 15861317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
    Wassmann S; Hilgers S; Laufs U; Böhm M; Nickenig G
    Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1208-12. PubMed ID: 12117739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.
    Lim S; Sakuma I; Quon MJ; Koh KK
    Int J Cardiol; 2013 Sep; 167(5):1696-702. PubMed ID: 23159411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?
    Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Santos RD; Bittencourt MS
    Clin Cardiol; 2018 Mar; 41(3):333-338. PubMed ID: 29574925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.